WO2004035001A3 - Calcium channel agonists for psychotherapeutic use - Google Patents

Calcium channel agonists for psychotherapeutic use Download PDF

Info

Publication number
WO2004035001A3
WO2004035001A3 PCT/US2003/032921 US0332921W WO2004035001A3 WO 2004035001 A3 WO2004035001 A3 WO 2004035001A3 US 0332921 W US0332921 W US 0332921W WO 2004035001 A3 WO2004035001 A3 WO 2004035001A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
learning
ameliorating
lvgcc
agonist
Prior art date
Application number
PCT/US2003/032921
Other languages
French (fr)
Other versions
WO2004035001A2 (en
Inventor
Mark G Barad
Christopher K Cain
Ashley M Blouin
Original Assignee
Univ California
Mark G Barad
Christopher K Cain
Ashley M Blouin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Mark G Barad, Christopher K Cain, Ashley M Blouin filed Critical Univ California
Priority to AU2003301258A priority Critical patent/AU2003301258A1/en
Publication of WO2004035001A2 publication Critical patent/WO2004035001A2/en
Publication of WO2004035001A3 publication Critical patent/WO2004035001A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a pharmaceutical composition comprising a therapeutically effective amount of an L-type voltage-gated calcium channels (LVGCC) agonist and a pharmaceutically acceptable carrier. The invention further provides methods of enhancing inhibitory learning in a subject, ameliorating schizophrenic symptoms in a subject, ameliorating symptoms of autism in a subject, reducing addiction in a subject, and ameliorating symptoms of anxiety disorder in a subject. The method comprises administering to the subject a therapeutically effective amount of an LVGCC agonist. In a typical embodiment, the inhibitory learning comprises extinction, latent inhibition, novel object recognition, negative contingency learning and/or inhibition of delay.
PCT/US2003/032921 2002-10-14 2003-10-14 Calcium channel agonists for psychotherapeutic use WO2004035001A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301258A AU2003301258A1 (en) 2002-10-14 2003-10-14 Calcium channel agonists for psychotherapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41799502P 2002-10-14 2002-10-14
US60/417,995 2002-10-14

Publications (2)

Publication Number Publication Date
WO2004035001A2 WO2004035001A2 (en) 2004-04-29
WO2004035001A3 true WO2004035001A3 (en) 2004-08-05

Family

ID=32107889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032921 WO2004035001A2 (en) 2002-10-14 2003-10-14 Calcium channel agonists for psychotherapeutic use

Country Status (2)

Country Link
AU (1) AU2003301258A1 (en)
WO (1) WO2004035001A2 (en)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS [online] KIRAC ET AL: "Bay K 8644 potentiates the anxiolytic effect of ethnol", Database accession no. 1991:577242 *
DATABASE HCAPLUS [online] SBERNA ET AL: "The amyloid b-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells", Database accession no. 1997:564273 *
DATABASE HCAPLUS [online] WEST ET AL: "Calcium channel agonist (-)-BAY k 8644 suppresses free and limited access intake of alcohol in genetic drinking rats", Database accession no. 1999:244194 *
J. OF NEUROCHEMISTRY, vol. 69, no. 3, 1997, pages 1177 - 1184 *
PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOUR, vol. 39, no. 2, 1991, pages 325 - 327 *
PSYCHOPHARMACOLOGY, vol. 142, no. 3, 1999, pages 261 - 269 *

Also Published As

Publication number Publication date
AU2003301258A8 (en) 2004-05-04
WO2004035001A2 (en) 2004-04-29
AU2003301258A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
GB0211398D0 (en) System and method for combining voice annotation and recognition search criteria with traditional search criteria into metadata
DE60329001D1 (en) 8-hydroxychinolinderivate
PT1727550E (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MX2009002310A (en) Pharmaceutical compositions of clonazepam and methods of use thereof.
WO2002076388A3 (en) Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
MY146986A (en) Methods for treating interleukin-6 related diseases
BRPI0408784A (en) method to use a compound
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
PL1699459T3 (en) Method for treatment of multiple sclerosis
AU2003249455A1 (en) System and method for scoring peptide matches
MA27188A1 (en) AMINO ACIDS WITH AFFINITY FOR ALPHA-2-DELTA PROTEIN
WO2004039247A3 (en) Compositions and methods for pain reduction
CA2632207C (en) Use of calcitonin for the treatment of ra
BR9909138A (en) Combination for the treatment of alcohol and drug addiction containing an opioid antagonist and a nmda receptor complex modulator
PL2051710T3 (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
WO2006000222A3 (en) The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
EP1540348A4 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
AU2003278806A1 (en) Composition and method for moisturizing nasal tissue
AU2003283217A1 (en) Method for determing predisposition to manifestation of immune system related diseases
WO2004035001A3 (en) Calcium channel agonists for psychotherapeutic use
AU2003251697A1 (en) Method for event synchronisation, especially for processors of fault-tolerant systems
WO2005123777A3 (en) Method of treating granuloma annulare or sarcoid
EP1387685A4 (en) Analgesic composition and method
WO2007149543A3 (en) Scar treatment using protein phosphatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP